Stocks Health care RGBP
OTC · Health careRegen BioPharma Inc (RGBP)
Regen BioPharma Inc brought in $236.6K of revenue over the twelve months to June 30, 2026, up 0.0% from a year earlier. It posted a net loss of $1.2M. At June 30, 2026 it held $239 in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 17, 2026.
Watch RGBP in 60 secondsWhat Regen BioPharma Inc does
Regen BioPharma Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker RGBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $236.6K | -$1.3M | -$0.05 | n/a |
| 2024 | $236.6K | -$668.3K | -$0.16 | n/a |
| 2023 | $236.6K | $1.2M | $0.29 | n/a |
| 2022 | $125.5K | $2.4M | $0.71 | n/a |
| 2021 | $61.2K | -$6.8M | -$0.00 | n/a |
| 2020 | $110K | $3.4M | $0.00 | n/a |
Full financial statements: income, balance sheet and cash flow
Where RGBP ranks in Health care
Latest SEC filings
What Regen BioPharma Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 17, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $59.1K versus the same quarter last year; diluted EPS $0.00 versus -$0.01.
- August 13, 2026Late quarterly report notice NT 10-Q
- July 15, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was flat at $59.1K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- March 4, 2026
- February 13, 2026Quarterly report 10-Q · period to December 31, 2025Revenue was flat at $59.1K versus the same quarter last year; diluted EPS -$0.01 versus -$0.13.
- February 2, 2026
- January 21, 2026Other event 8-K
- January 12, 2026Form QUALIF filing QUALIF
- January 8, 2026Form 1-A POS filing 1-A POS
Who owns RGBP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Quick Capital, LLC13G, passive | 9.9% | September 12, 2025 |
Largest institutional holders
Insiders
Questions about RGBP
What does Regen BioPharma Inc do?
Regen BioPharma Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker RGBP.
Is Regen BioPharma Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $1.2M on revenue of $236.6K.
How much revenue does Regen BioPharma Inc make?
Over the twelve months to June 30, 2026 Regen BioPharma Inc reported revenue of $236.6K. That is 0.0% more than a year earlier.
When did Regen BioPharma Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 17, 2026. It covers the period to June 30, 2026.
Similar companies
Compare RGBP with
Follow RGBP
Get an email when Regen BioPharma Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow RGBP: get an email when it filesWhere the numbers come from
Financial figures are the values Regen BioPharma Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.